---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-047207"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:23:18.352022+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Maze Therapeutics: Q4 net loss $29.6M, FY net income $52.2M on $167.5M license revenue; cash runway into H2 2027

## Summary
- Q4 net loss $29.6M vs $26.6M loss a year ago; FY net income $52.2M vs $100.4M loss in 2023.
- Cash and cash equivalents $196.8M as of Dec 31, 2024, up from $29.2M; combined with Feb 2025 IPO proceeds of $140M provides runway into H2 2027.
- License revenue of $167.5M in FY2024 primarily from $150M upfront from Shionogi for MZE001.
- Phase 2 HORIZON trial of MZE829 for AKD dosing patients; initial data expected Q1 2026.
- Phase 1 trial of MZE782 ongoing; initial data including proof-of-mechanism expected H2 2025.

## SEC filing metadata
- accession: 0000950170-25-047207
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/0000950170-25-047207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/maze-8k-q424_earnings.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-047207
- JSON: https://secwatch.observer/filing/0000950170-25-047207.json
- Plain text: https://secwatch.observer/filing/0000950170-25-047207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.